Characterization of a highly conserved domain within the severe acute respiratory syndrome coronavirus spike protein S2 domain with characteristics of a viral fusion peptide
- PMID: 19439480
- PMCID: PMC2708636
- DOI: 10.1128/JVI.00079-09
Characterization of a highly conserved domain within the severe acute respiratory syndrome coronavirus spike protein S2 domain with characteristics of a viral fusion peptide
Abstract
Many viral fusion proteins are primed by proteolytic cleavage near their fusion peptides. While the coronavirus (CoV) spike (S) protein is known to be cleaved at the S1/S2 boundary, this cleavage site is not closely linked to a fusion peptide. However, a second cleavage site has been identified in the severe acute respiratory syndrome CoV (SARS-CoV) S2 domain (R797). Here, we investigated whether this internal cleavage of S2 exposes a viral fusion peptide. We show that the residues immediately C-terminal to the SARS-CoV S2 cleavage site SFIEDLLFNKVTLADAGF are very highly conserved across all CoVs. Mutagenesis studies of these residues in SARS-CoV S, followed by cell-cell fusion and pseudotyped virion infectivity assays, showed a critical role for residues L803, L804, and F805 in membrane fusion. Mutation of the most N-terminal residue (S798) had little or no effect on membrane fusion. Biochemical analyses of synthetic peptides corresponding to the proposed S2 fusion peptide also showed an important role for this region in membrane fusion and indicated the presence of alpha-helical structure. We propose that proteolytic cleavage within S2 exposes a novel internal fusion peptide for SARS-CoV S, which may be conserved across the Coronaviridae.
Figures
![FIG. 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2708636/bin/zjv0150921240001.gif)
![FIG. 2.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2708636/bin/zjv0150921240002.gif)
![FIG. 3.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2708636/bin/zjv0150921240003.gif)
![FIG. 4.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2708636/bin/zjv0150921240004.gif)
![FIG. 5.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2708636/bin/zjv0150921240005.gif)
![FIG. 6.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2708636/bin/zjv0150921240006.gif)
![FIG. 7.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2708636/bin/zjv0150921240007.gif)
![FIG. 8.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2708636/bin/zjv0150921240008.gif)
![FIG. 9.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2708636/bin/zjv0150921240009.gif)
![FIG. 10.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2708636/bin/zjv0150921240010.gif)
Similar articles
-
SARS-coronavirus spike S2 domain flanked by cysteine residues C822 and C833 is important for activation of membrane fusion.Virology. 2009 Oct 25;393(2):265-71. doi: 10.1016/j.virol.2009.07.038. Epub 2009 Aug 29. Virology. 2009. PMID: 19717178 Free PMC article.
-
Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites.Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5871-6. doi: 10.1073/pnas.0809524106. Epub 2009 Mar 24. Proc Natl Acad Sci U S A. 2009. PMID: 19321428 Free PMC article.
-
The spike protein of SARS-CoV--a target for vaccine and therapeutic development.Nat Rev Microbiol. 2009 Mar;7(3):226-36. doi: 10.1038/nrmicro2090. Epub 2009 Feb 9. Nat Rev Microbiol. 2009. PMID: 19198616 Free PMC article. Review.
-
Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus spike protein.J Virol. 2005 Jun;79(11):7195-206. doi: 10.1128/JVI.79.11.7195-7206.2005. J Virol. 2005. PMID: 15890958 Free PMC article.
-
The SARS-CoV S glycoprotein.Cell Mol Life Sci. 2004 Oct;61(19-20):2428-30. doi: 10.1007/s00018-004-4257-y. Cell Mol Life Sci. 2004. PMID: 15526150 Free PMC article. Review.
Cited by
-
Functional and antigenic characterization of SARS-CoV-2 spike fusion peptide by deep mutational scanning.Nat Commun. 2024 May 14;15(1):4056. doi: 10.1038/s41467-024-48104-8. Nat Commun. 2024. PMID: 38744813 Free PMC article.
-
Synergistic peptide combinations designed to suppress SARS-CoV-2.Heliyon. 2024 Apr 29;10(9):e30489. doi: 10.1016/j.heliyon.2024.e30489. eCollection 2024 May 15. Heliyon. 2024. PMID: 38726116 Free PMC article.
-
The Effects of Chloroquine and Hydroxychloroquine on ACE2-Related Coronavirus Pathology and the Cardiovascular System: An Evidence-Based Review.Function (Oxf). 2020 Jul 27;1(2):zqaa012. doi: 10.1093/function/zqaa012. eCollection 2020. Function (Oxf). 2020. PMID: 38626250 Free PMC article.
-
Vero cell-adapted SARS-CoV-2 strain shows increased viral growth through furin-mediated efficient spike cleavage.Microbiol Spectr. 2024 Apr 2;12(4):e0285923. doi: 10.1128/spectrum.02859-23. Epub 2024 Feb 28. Microbiol Spectr. 2024. PMID: 38415690 Free PMC article.
-
Development of SARS-CoV-2 entry antivirals.Cell Insight. 2024 Jan 30;3(1):100144. doi: 10.1016/j.cellin.2023.100144. eCollection 2024 Feb. Cell Insight. 2024. PMID: 38323318 Free PMC article. Review.
References
-
- Bosch, B. J., and P. J. Rottier. 2008. Nidovirus Entry into Cells, p. 157-178. In S. Perlman, T. Gallagher, and E. J. Snijder (ed.), Nidoviruses. ASM Press, Washington, DC.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous